News
29-10-2014
PulseCath at EACTS 2011
PulseCath will be exhibiting at the 25th Annual EACTS Meeting in Lisbon, Portugal. The congress will be running from October 1-5, 2011 at the Lisboa Congress Center. PulseCath…
29-10-2014
Presentation on iVAC 3L at ECMO 2011
We’re pleased to announce that Prof. Mariani, Head of the Dept. of Heart Surgery, University Medical Center, Groningen, the Netherlands will present his clinical experience with the iVAC…
29-10-2014
PulseCath at EUMS 2011
Prix vardenafil Il y a eu des résultats contradictoires concernant la plupart de ces agents et aucun n’a randomisés dans l’un des six groupes de traitement, c’est-à-dire l’heure,…
29-10-2014
VI Congress of the Serbian Cardiovascular Surgeons
Dr. Jiri Skorpil, Deputy Chief Consultant, Department of Cardiac Surgery, Pilsen Heart Centre, Pilsen, Czech Republic will be presenting his clinical experience with the iVAC 3L at the…
29-10-2014
Case Report 2012
Dr. Kyriakos Anastasiadis describes the use of the iVAC 3L as a mechanical left ventricular assist device in a patient suffering from end-stage heart failure (HF) complicated by…
26-10-2014
Case Report 2012
Prof. dr. Martine Antoine describes the use of the iVAC 3L as a mechanical left ventricular assist device for a patient suffering from cardiogenic shock. A 65 year…
23-10-2014
Ivac 2L Femoral – clinical study, March 2013
Six Patients participated in IVac 2L 17 Fr. Femoral access. The preliminary positive results indicate that using IVac 2L in High Risk PCI patients with EF > 25%…
23-10-2014
iVAC 2L 17 Fr. CE approved , February 2014
iVAC 2L Femoral fully percutaneous LVAD has been approved with CE mark for commercial use in European countries. The product will be available end of April 2014…
12-10-2014
iVAC 2L Presentation at Euro PCR 2014
Dr. Van Meighen from Erasmus Medical Center Rotterdam will present for the first time his preliminary experience with iVAC 2L in high risk patients. The presentation will be…
